Abstract
The effects of the imidazoline compound RX871024 on arginine-induced insulin, glucagon, and somatostatin secretion in the isolated perfused rat pancreas have been investigated. Arginine induced biphasic insulin, glucagon, and somatostatin release when infused for 20 min at 20 mM concentration and 3.3 mM glucose in the medium. RX871024, at 10 μM, did not influence basal hormone secretion but enhanced arginine-stimulated insulin and somatostatin release. In contrast, glucagon secretion was markedly inhibited by 10 μM imidazoline. RX871024 (1 μM) did not significantly affect arginine-induced insulin and somatostatin secretion but had an inhibitory effect on the second phase of glucagon release. In conclusion, RX871024 exerts a complex effect on the endocrine pancreas challenged by arginine, comprising stimulation of insulin and somatostatin release and inhibition of glucagon release. These effects on hormone release probably constitute the main mechanism of the antidiabetogenic action of the imidazolines.
| Original language | English |
|---|---|
| Pages (from-to) | 162-165 |
| Number of pages | 4 |
| Journal | Biochemical and Biophysical Research Communications |
| Volume | 252 |
| Issue number | 1 |
| DOIs | |
| State | Published - Nov 9 1998 |
| Externally published | Yes |
Fingerprint
Keywords
- Glucagon
- Imidazoline
- Insulin
- Perfused rat pancreas
- Somatostatin
ASJC Scopus subject areas
- Biochemistry
- Biophysics
- Molecular Biology
Cite this
Effects of imidazoline derivative RX871024 on insulin, glucagon, and somatostatin secretion from isolated perfused rat pancreas. / Efanova, I. B.; Zaitsev, S. V.; Efanov, A. M.; Östenson, C. G.; Raap, A.; Mest, H. J.; Berggren, P. O.; Efendić, S.
In: Biochemical and Biophysical Research Communications, Vol. 252, No. 1, 09.11.1998, p. 162-165.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of imidazoline derivative RX871024 on insulin, glucagon, and somatostatin secretion from isolated perfused rat pancreas
AU - Efanova, I. B.
AU - Zaitsev, S. V.
AU - Efanov, A. M.
AU - Östenson, C. G.
AU - Raap, A.
AU - Mest, H. J.
AU - Berggren, P. O.
AU - Efendić, S.
PY - 1998/11/9
Y1 - 1998/11/9
N2 - The effects of the imidazoline compound RX871024 on arginine-induced insulin, glucagon, and somatostatin secretion in the isolated perfused rat pancreas have been investigated. Arginine induced biphasic insulin, glucagon, and somatostatin release when infused for 20 min at 20 mM concentration and 3.3 mM glucose in the medium. RX871024, at 10 μM, did not influence basal hormone secretion but enhanced arginine-stimulated insulin and somatostatin release. In contrast, glucagon secretion was markedly inhibited by 10 μM imidazoline. RX871024 (1 μM) did not significantly affect arginine-induced insulin and somatostatin secretion but had an inhibitory effect on the second phase of glucagon release. In conclusion, RX871024 exerts a complex effect on the endocrine pancreas challenged by arginine, comprising stimulation of insulin and somatostatin release and inhibition of glucagon release. These effects on hormone release probably constitute the main mechanism of the antidiabetogenic action of the imidazolines.
AB - The effects of the imidazoline compound RX871024 on arginine-induced insulin, glucagon, and somatostatin secretion in the isolated perfused rat pancreas have been investigated. Arginine induced biphasic insulin, glucagon, and somatostatin release when infused for 20 min at 20 mM concentration and 3.3 mM glucose in the medium. RX871024, at 10 μM, did not influence basal hormone secretion but enhanced arginine-stimulated insulin and somatostatin release. In contrast, glucagon secretion was markedly inhibited by 10 μM imidazoline. RX871024 (1 μM) did not significantly affect arginine-induced insulin and somatostatin secretion but had an inhibitory effect on the second phase of glucagon release. In conclusion, RX871024 exerts a complex effect on the endocrine pancreas challenged by arginine, comprising stimulation of insulin and somatostatin release and inhibition of glucagon release. These effects on hormone release probably constitute the main mechanism of the antidiabetogenic action of the imidazolines.
KW - Glucagon
KW - Imidazoline
KW - Insulin
KW - Perfused rat pancreas
KW - Somatostatin
UR - http://www.scopus.com/inward/record.url?scp=0032501150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032501150&partnerID=8YFLogxK
U2 - 10.1006/bbrc.1998.9635
DO - 10.1006/bbrc.1998.9635
M3 - Article
C2 - 9813163
AN - SCOPUS:0032501150
VL - 252
SP - 162
EP - 165
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
SN - 0006-291X
IS - 1
ER -